Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Werewolf Therapeutics, Inc. - Common Stock
(NQ:
HOWL
)
0.9281
+0.0466 (+5.29%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Werewolf Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Halper Sadeh LLC is Investigating Whether HOWL, BZH, MKTX, LNTH are Obtaining Fair Deals for their Shareholders
September 24, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
September 24, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
September 09, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
September 03, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether HOWL, BZH, MKTX, CBZ are Obtaining Fair Deals for their Shareholders
August 24, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ)
August 24, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
August 23, 2026
From
Halper Sadeh LLC
Via
Business Wire
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
August 21, 2026
From
Ambros Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
July 31, 2026
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
May 07, 2026
– Company continues to evaluate strategic options to maximize shareholder value –
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
March 27, 2026
Company continues to evaluate strategic options to maximize shareholder value
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
February 24, 2026
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces Pipeline and Business Updates
December 18, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
November 07, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 04, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
October 08, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
October 03, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
July 09, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the BIO International Convention
June 12, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
May 29, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
May 20, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
May 13, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
May 05, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
May 05, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
April 17, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 11, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
